Want to see NL:LKFT full AI Analyst Report?
Top Page
Lakefront Biotherapeutics NV
(LKFT)
Select Model
Select Model
Rating:66Neutral
Price Target:
€30.00
▲(17.92% Upside)
Action:Reiterated
Date:08/20/26
The score is primarily driven by a split financial profile: an exceptionally strong, low-debt balance sheet and recently improved profitability are tempered by ongoing negative operating/free cash flow and uneven revenue momentum. Technical indicators are mildly weak (negative MACD; below the 200-day average), while the low P/E provides meaningful valuation support.
Positive Factors
Conservative Balance Sheet
Near-zero leverage and a large equity base provide substantial financial resilience, reducing balance-sheet pressure while the company funds operations and investment. This conservative financial structure gives management greater flexibility to withstand volatility and pursue opportunities.
Negative Factors
Persistent Cash Burn
Persistent negative operating and free cash flow means the business is not currently self-funding, despite reported profitability. Continued cash burn can consume financial resources, increase reliance on the balance sheet, and constrain the company’s ability to invest or absorb setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Near-zero leverage and a large equity base provide substantial financial resilience, reducing balance-sheet pressure while the company funds operations and investment. This conservative financial structure gives management greater flexibility to withstand volatility and pursue opportunities.
Read all positive factors
Lakefront Biotherapeutics NV (LKFT) vs. iShares MSCI Netherlands ETF (EWN)
Market Cap
€1.86B
Dividend YieldN/A
Average Volume (3M)99.74K
Price to Earnings (P/E)3.8
Beta (1Y)0.57
Revenue Growth259.41%
EPS GrowthN/A
CountryNL
Employees452
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)7.39
Shares Outstanding65,897,070
10 Day Avg. Volume67,439
30 Day Avg. Volume99,739
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.95Price Target Upside-1.93% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-2.53
Revenue Forecast (FY)€27.85M
Lakefront Biotherapeutics NV Business Overview & Revenue Model
Company Description
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in der...
How the Company Makes Money
null...
Lakefront Biotherapeutics NV Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.04B | 1.11B | 275.65M | 239.72M | 505.28M | 484.85M |
| Gross Profit | 1.02B | 1.03B | 240.79M | 203.74M | 493.20M | 483.22M |
| EBITDA | 347.15M | 521.51M | 43.33M | 51.04M | 3.87M | -100.93M |
| Net Income | 488.78M | 320.88M | 74.08M | 211.70M | -217.99M | -125.42M |
Balance Sheet | ||||||
| Total Assets | 3.37B | 3.41B | 4.14B | 4.36B | 4.73B | 5.19B |
| Cash, Cash Equivalents and Short-Term Investments | 2.98B | 3.00B | 3.12B | 3.68B | 4.09B | 4.70B |
| Total Debt | 6.43M | 6.92M | 11.72M | 9.60M | 21.90M | 26.86M |
| Total Liabilities | 119.06M | 170.65M | 1.24B | 1.56B | 2.21B | 2.55B |
| Stockholders Equity | 3.25B | 3.24B | 2.90B | 2.80B | 2.53B | 2.64B |
Cash Flow | ||||||
| Free Cash Flow | -301.12M | -210.71M | -402.14M | -425.24M | -537.49M | -561.71M |
| Operating Cash Flow | -292.39M | -197.01M | -320.03M | -405.97M | -500.54M | -503.83M |
| Investing Cash Flow | 256.36M | 228.37M | 220.60M | 71.19M | -1.25B | 541.24M |
| Financing Cash Flow | -2.77M | -3.27M | -4.92M | -5.00M | -1.49M | -3.88M |
Lakefront Biotherapeutics NV Technical Analysis
Positive
25.44
Price Trends
25.57
Positive
25.29
Positive
25.83
Positive
Market Momentum
0.63
Negative
67.57
Neutral
93.07
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:LKFT, the sentiment is Positive. The current price of 25.44 is below the 20-day moving average (MA) of 26.60, below the 50-day MA of 25.57, and below the 200-day MA of 25.83, indicating a bullish trend. The MACD of 0.63 indicates Negative momentum. The RSI at 67.57 is Neutral, neither overbought nor oversold. The STOCH value of 93.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NL:LKFT.
Lakefront Biotherapeutics NV Risk Analysis
Lakefront Biotherapeutics NV disclosed 79 risk factors in its most recent earnings report. Lakefront Biotherapeutics NV reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We are dependent on the transfer of the Jyseleca business, including the European and UK Marketing Authorizations, the commercial, medical affairs and development activities for Jyseleca and approximately 400 Galapagos positions in 14 European countries, to Alfasigma. Q4, 2023
2.
Risks associated to the legal uncertainty around the Unitary patent court in Europe Q4, 2023
3.
If approved, our investigational products regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway. Q4, 2023
Lakefront Biotherapeutics NV Peers Comparison
UnderperformOutperform
Sector (55)
NL:LKFT
Lakefront Biotherapeutics NV
28.22
1.06
3.90%
NL:PHARM
Pharming Group
1.05
-0.09
-8.27%
NL:VVY
Vivoryon Therapeutics AG
0.84
-0.79
-48.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.